Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 2/20 | 0.45 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | GFRA3 | O60609 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14437215 | 1.00 | SRD5A1 (0.45) | SRD5A1CAMK2APGRGFRA3RET | |
| SCHEMBL2435536 | 1.00 | SRD5A1 (0.45) | SRD5A1CAMK2APGRGFRA3RET | |
| SCHEMBL227502 | 1.00 | SRD5A1 (0.45) | SRD5A1CAMK2APGRGFRA3RET | |
| SCHEMBL31650212 | 0.89 | CAMK2A (0.50) | SRD5A1CAMK2APGRKDM1ASLC6A4 | |
| SCHEMBL7679993 | 0.89 | CAMK2A (0.50) | SRD5A1CAMK2APGRKDM1ASLC6A4 | |
| SCHEMBL16794356 | 0.87 | CAMK2A (0.49) | SRD5A1CAMK2APGRKDM1ASLC6A4 | |
| SCHEMBL9276752 | 0.84 | HTR2A (0.46) | SRD5A1CAMK2AKDM1AHTR2AHTR2C | |
| SCHEMBL1576024 | 0.84 | HTR2A (0.46) | SRD5A1CAMK2AKDM1AHTR2AHTR2C | |
| SCHEMBL3638981 | 0.84 | HTR2A (0.46) | SRD5A1CAMK2AKDM1AHTR2AHTR2C | |
| SCHEMBL27887272 | 0.78 | KDM1A (0.42) | SRD5A1CAMK2AKDM1ASLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2026-05-28 | — | — | US | disclosed |
| EP-4605395-A2 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | Dong-A ST Co., Ltd. (KR) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024084448-A2 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2024-04-25 | — | — | WO | disclosed |
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | KSQ Therapeutics, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | KSQ Therapeutics, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | KSQ Therapeutics, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230203046-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20230203046-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20230203046-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | US | disclosed |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | US | disclosed |
| WO-2012101011-A2 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20100029710-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES | PFIZER PRODUCTS INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029710-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES | PFIZER PRODUCTS INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029710-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES | PFIZER PRODUCTS INC. (US) | 2010-02-04 | — | — | US | disclosed |
| CN-101600715-A | Compound with angiotensin-ii receptor antagonistic action and PPAR γ activating activities | PFIZER PROD INC (US) | 2009-12-09 | — | — | CN | disclosed |
| EP-2125806-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARY ACTIVATING ACTIVITIES | Pfizer Products Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008084303-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARY ACTIVATING ACTIVITIES | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008084303-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARY ACTIVATING ACTIVITIES | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | USP1, UPP1, USP2 | SRD5A1 1142/4885CAMK2A 3663/4885PGR 2091/4885 |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | SRD5A1 4334/4885CAMK2A 796/4885PGR 4682/4885 |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | CYP1A1, AHR, CYP1B1 | SRD5A1 3600/4885CAMK2A 1778/4885PGR 576/4885 |
| US-20230203046-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, UPP1, USP2 | SRD5A1 1142/4885CAMK2A 3663/4885PGR 2091/4885 |
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | AXL, ERBB2, ERBB3 | SRD5A1 2020/4885CAMK2A 419/4885PGR 1798/4885 |
| US-20100029710-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES | AGTR2, AGTR1, AGT | SRD5A1 1743/4885CAMK2A 312/4885PGR 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.